Inhibition of TG2 has been shown to increase drug-induced apoptosis in several cancer cell lines and evaluated as a sensitizer to chemotherapy in preclinical animal models of breast, ovarian, non-small cell lung, melanoma, colon cancers, glioblastoma, and meningioma [117,122,123,126,127,141]. Here, TGM2 is linked to malignant colon neoplasm.